NCT07493590Not yet recruiting
CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction
CAPTURE-HFpEF (Cardiovascular Assessment and Phenotyping for Timely Understanding and Recognition of Evolving Heart Failure With Preserved Ejection Fraction)
Source: ClinicalTrials.gov · Last updated 25 Mar 2026
Brief summary (registry, in English)
The goal of this observational study is to improve early detection, characterization, and understanding of heart failure with preserved ejection fraction (HFpEF) in adults at risk of or diagnosed with HFpEF, including men and women across Danish regions. The main questions to answer are: Can systematic cardiovascular screening and deep phenotyping improve early identification and classification of HFpEF? Which clinical, imaging, biomarker, and metabolic characteristics define subtypes (phenotypes) of HFpEF and predict disease progression and outcomes? Researchers will compare participants with HFpEF, participants at risk of HFpEF, and relevant control groups to see if differences in biomarkers, imaging findings, and clinical characteristics can identify early disease stages and distinct HFpEF phenotypes. Participants identified with HFpEF will: * Undergo detailed cardiovascular examinations (e.g., echocardiography, CT and other imaging examinations, RHC, CPET) * Provide blood and tissue samples for biomarker and metabolic analyses * Complete clinical assessments and questionnaires * Have relevant health data collected from national health registries * Attend follow-up assessments to monitor disease progression
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30000 (estimated)
- First submitted
- 16 Mar 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Apr 2033
- Lead sponsor
- Herlev and Gentofte Hospital
- Diseases
- Heart failure
- NCT number
- NCT07493590
What you commit to
- Study type: Observational
- Planned participants: 30000
- From 1 Apr 2026 to the primary completion date, 1 Apr 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior organ-transplantation
Other illness
- Cancer \<1 year
- Dementia
Age
- Age \>90 years
Other
- Dialysis
- COPD and O2
- Nursing home
- Known dilated cardiomyopathy
- Amyloidosis
Who the study is looking for
- Patients \>60 years with ≥1 risk factor, OR
- Patients \>50 years with ≥2 risk factors
- Hypertension
- Type 1 or 2 diabetes
- Chronic kidney disease (eGFR \<60 mL/min/1.73 m²)
- Previous cardiotoxic drug exposure
- atrial fibrillation
- Ischemic heart disease
- Previous heart valve surgery/intervention
- Body mass index \>30 kg/m² (self-reported)
- Use of ≥40 mg furosemide
- Obstructive sleep apnea
- Non-alcoholic fatty liver disease
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Herlev and Gentofte Hospital Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.